Original Source(s)
Related Content
FDA Expands Pediatric Roflumilast Use
The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.
June 30, 2026
-
3 min